FARAWATCH featuring FARAPULSE PFA, WATCHMAN FLX Pro and VersaCross Connect for AF treatment and stroke protection

Concomitant AF Treatment + Stroke Protection

With the FARAPULSE™ PFA Platform and WATCHMAN FLX™ Pro LAAC Device 

2 Proven Procedures. 1 Streamlined Case. 1 Patient Recovery.

FARAWATCH wordmark for concomitant AF ablation and stroke protection

Concomitant FARAWATCH™ procedures using the FARAPULSE™ PFA Platform and WATCHMAN FLX™ Pro LAAC Device enable physicians to effectively treat AF patients while providing stroke protection in one streamlined case and recovery process.

The VersaCross Connect Access Solution for FARADRIVE provides an integrated zero exchange transseptal workflow and supports seamless integration between the FARAPULSE PFA Platform and WATCHMAN FLX Pro LAAC Device.
Together, we can transform AF care.

Why concomitant FARAPULSE PFA and WATCHMAN LAAC?

  • Streamlined approach that benefits patients, increases operational efficiency, and reduces resource burden​​
  • Patients and physicians can feel confident they are addressing both the symptoms of AF while reducing the risk of stroke and bleeding at the same time​
  • The most widely used technologies in PFA and LAAC, the FARAPULSE Platform and the WATCHMAN FLX Pro LAAC Device lead the way in enabling safe and efficient AF treatment and stroke protection
  • In post-ablation patients, WATCHMAN demonstrated similar efficacy to oral anticoagulation while significantly reducing bleeding events through 36 months
  • A unified workflow from access through procedure completion, supporting AF treatment and stroke protection in one streamlined case
500,000+ FARAPULSE patients and
600,000+ WATCHMAN patients have been treated globally


 

Clinically Proven

The FARAPULSE Platform and WATCHMAN LAAC Device lead the way in clinical evidence for their therapy offerings:

The FARAPULSE Platform has built the largest and most comprehensive clinical evidence base in pulsed field ablation, with unmatched volume in peer-reviewed studies, registry participation, and patient outcomes across pivotal trials and real-world registries.

Explore more on clinical data with FARAPULSE

The OPTION Clinical Trial3,5, a breakthrough study in AF treatment, is the first randomized, head-to-head study comparing WATCHMAN to OAC (95% DOACs) after cardiac ablation*.

Concomitant & Sequential Cohort Subanalysis

*Thermal AF ablation only.

OPTION demonstrated non-inferior efficacy compared with oral anticoagulation and a statistically significant reduction in bleeding through 36 months.
Concomitant and sequential LAAC approaches demonstrated comparable efficacy outcomes.


 

FARAWATCH Procedure Workflow

Discover Boston Scientific’s comprehensive concomitant FARAWATCH workflow featuring FARAPULSE PFA and WATCHMAN LAAC, showcasing a unified procedural pathway for rhythm management and stroke protection.


 

The Leaders in AF Treatment and Stroke Protection

FARAPULSE PFA Platform wordmark
FARAPULSE Pulsed Field Ablation platform for AF ablation procedures

The FARAPULSE platform is designed as an end-to-end PFA workflow solution that minimizes procedural steps and reduces potential risks to the patient. With a zero-exchange integrated transseptal access solution and map-and-ablate catheters, FARAPULSE PFA supports a streamlined experience optimized for patient outcomes and operator peace of mind. ​​

  • 500,000+ patients treated
  • <1% Real-World Major Adverse Event Rate1†
  • Zero Cases of Thermal Injuries1
  • VersaCross Connect™ Access Solution for FARADRIVE™ facilitated 100% transseptal crossing success in FARAPULSE PFA procedures4
  • 270+ clinical trials and publications
Explore FARAPULSE PFA
WATCHMAN LAAC Solutions wordmark
WATCHMAN FLX Pro left atrial appendage closure device for stroke risk reduction

Built on the 20+ year proven performance of the world's most studied LAAC device, WATCHMAN FLX Pro helps patients reduce their AF-related stroke risk - without the need for long-term OACs. ​

  • 600,000+ patients treated
  • 0.2% Major Adverse Event Rate2
  • Non-Inferior Efficacy, Superior Safety to OACs Post-Ablation3
  • Non-inferior to NOACs for CV death, stroke and systemic embolism in CHAMPION-AF5
  • Superior to NOACs for ISTH non-procedural major bleeding and modified* clinically relevant non-major bleeding in CHAMPION-AF5
  • 1,000+ clinical trials and publications
Explore WATCHMAN LAAC


 

Hear from the Expert: Concomitant AF Ablation and LAAC

Dr Domenico Della Rocca shares his experience with concomitant procedures, patient selection and procedural efficiency.


 

VersaCross RF Wire pigtail configuration, protruding from VersaCross Connect Transseptal Dilator/FARADRIVE sheath assembly.
VersaCross Connect™ Access Solution for FARADRIVE™
The Boston Scientific VersaCross Connect™ LAAC Access Solution
VersaCross Connect™ LAAC Access Solution

FARAPULSE Sites:
Visit the Patient site
Visit the Referring HCP site

WATCHMAN Sites:
Visit the Patient site
Visit the Referring HCP site


† MAE data reflect outcomes from a real-world registry. SAE rate of 2.1% observed in the ADVENT Pivotal Trial evaluating the FARAPULSE™ Pulsed Field Ablation System. Source: Reddy, Vivek Y., et al. “Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation.” New England Journal of Medicine 389.18 (2023): 1660-1671.

References

  1. Ekanem E, Reddy VY, et al. Multi-National Survey on the Safety of the post-approval clinical use of Pulsed Field Ablation in 17,000 + patients (MANI FEST 17K)
    *Defined as the occurrence of death, stroke, esophageal fistula or dysmotility, pulmonary vein stenosis, persistent phrenic nerve injury, pericardial tamponade, vascular complication, coronary artery spasm, hemolysis, or thrombosis
  2. Piccini et al. Poster Presentation. HRS 2 025.
    *Defined as the occurrence of all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention between device implantation and seven days or hospital discharge (whichever is later). Includes device or procedure related events requiring open cardiac surgery or major endovascular intervention such as pseudoaneurysm repair, AV fistula repair, or other major endovascular repair.
  3. Wazni O, et al. New England Journal of Medicine, November 2024 . Primary Efficacy: Stroke, mortality, systemic embolism. Primary Safety: Non-procedural ISTH major and clinically-relevant non-major bleeding
  4. Eckart R, et al. Heart Rhythm O2. July 2025;In-Press:1-8. doi:10.1016/j.hroo.2025.07.014
  5. SK Doshi et al. Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation. New England Journal of Medicine, March 2026


CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.